The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price target ...

This guide covers all the logo design rules, best practices, tips, examples, and more to equip you with the knowledge for crafting brilliant logos. Logos are one of the most vital elements of any ...

From its origins in a garage to becoming one of the most recognisable symbols in the world, explore the story behind the iconic Apple logo design. Apple is a company that has changed the technology ...

Alnylam’s second showing on this list is for its Sanofi-partnered siRNA therapy fitusiran, which the companies proposed for the treatment of hemophilia A and B. The FDA’s verdict is expected on March ...

We are always excited about a new PowerToys utility/feature upgrade, and this time it’s related to the Run utility. After recently adding video transcoding capabilities in the app, Microsoft ...

South Africa's competition watchdog probes Novo Nordisk and Sanofi for potential anti-competitive practices in the insulin pen market South Africa’s competition watchdog is investigating ...

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market. South Africa’s Competition ...

March 4 (Reuters) - South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive practices in the human insulin pen market, the authority ...

Results from those studies in 2019 enabled the Sanofi and Regeneron antibody to become the first treatment approved by the FDA in inadequately controlled CRSwNP. Dupixent’s 52-week placebo ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologics’ novel immune checkpoint inhibitor, the French pharma is handing the prospect back to Biond. The move is due ...